Details

Autor(en) / Beteiligte

• Kantarjian, Hagop
• Stein, Anthony
• Gökbuget, Nicola
• Fielding, Adele K
• Schuh, Andre C
• Ribera, Josep-Maria
• Wei, Andrew
• Dombret, Hervé
• Foà, Robin
• Bassan, Renato
• Arslan, Önder
• Sanz, Miguel A
• Bergeron, Julie
• Demirkan, Fatih
• Lech-Maranda, Ewa
• Rambaldi, Alessandro
• Thomas, Xavier
• Horst, Heinz-August
• Brüggemann, Monika
• Klapper, Wolfram
• Wood, Brent L
• Fleishman, Alex
• Nagorsen, Dirk
• Holland, Christopher
• Zimmerman, Zachary
• Topp, Max S

Titel

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Ist Teil von

• The New England journal of medicine, 2017-03, Vol.376 (9), p.836-847

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2017

Link zum Volltext

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• Among adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, treatment with the bispecific anti-CD19 and anti-CD3 monoclonal antibody blinatumomab resulted in longer overall survival and higher remission rates than did chemotherapy. The prognosis for adults with newly diagnosed acute lymphoblastic leukemia (ALL) has improved over the past three decades. With the use of intensive chemotherapy regimens, complete remission rates are 85 to 90% and long-term survival rates are 30 to 50%. 1 – 4 Still, most adults with B-cell precursor ALL will have a relapse and will die from complications of resistant disease or associated treatment. Among adults with relapsed or refractory ALL, remission rates are 18 to 44% with the use of standard salvage chemotherapy, but the duration of remission is typically short. 5 – 10 A major goal in this population is to . . .